EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

Sila Oksuz iD, Oguzcan Kinikoglu iD, Ugur Ozkerim iD, Deniz Isik iD, Heves Surmeli iD, Seval Ay iD, Hatice Odabas iD, Nedim Turan iD

Journal of Clinical Medicine · 28.02.2026 · 15 (5) · 1853

DOI: 10.3390/jcm15051853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.02.2026. Verfasst von Sila Oksuz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antibiotic exposure has been shown to negatively affect immune checkpoint inhibitor (ICI) efficacy in several cancers, possibly by disrupting gut microbiota. It represents a potentially modifiable clinical factor that may influence immunotherapy efficacy in RCC. However, data on renal cell carcinoma (RCC) remain limited, especially regarding prognostic risk groups.

Methods

We conducted a retrospective cohort study of 120 RCC patients treated with ICIs between 2018 and 2024 at Kartal Dr. Lütfi Kırdar City Hospital. Patients were classified based on systemic antibiotic exposure within ±30 days of ICI start. Survival outcomes were compared using Kaplan–Meier and Cox regression analyses. Subgroup analyses were performed according to the International Metastatic RCC Database Consortium (IMDC) risk classification.

Results

Of the 120 patients, 38 (31.7%) received antibiotics during the peri-ICI period. Median progression-free survival (PFS) was significantly shorter in the antibiotic-exposed group (5.1 vs. 9.4 months; p = 0.004), as was overall survival (OS) (14.8 vs. 22.5 months; p = 0.03). Antibiotic use remained an independent predictor of both PFS (HR = 1.87; 95% CI: 1.21–2.89) and OS (HR = 1.64; 95% CI: 1.04–2.59). In subgroup analyses, intermediate-risk patients had worse OS with antibiotics (13.5 vs. 20.6 months; p = 0.035), as did poor-risk patients (8.1 vs. 13.9 months; p = 0.049).

Conclusions

Antibiotic exposure during the peri-immunotherapy period is linked to significantly poorer outcomes in RCC patients, especially those with intermediate and poor IMDC risk scores. These findings emphasize the importance of antimicrobial stewardship and suggest a potential role for microbiome-informed patient management in RCC.

Schlagwörter

Stichwörter der Autor:innen

IMDC risk classificationantibiotic exposuredysbiosisgut microbiotaimmune checkpoint inhibitorsoverall survivalprogression-free survivalrenal cell carcinoma

Autor:innen und Institutionen

  • Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.

ORCID-Profile: Sila Oksuz, Oguzcan Kinikoglu, Ugur Ozkerim, Deniz Isik, Heves Surmeli, Seval Ay, Hatice Odabas, Nedim Turan

Zitieren

APA

Oksuz, S., Kinikoglu, O., Ozkerim, U., Isik, D., Surmeli, H., Ay, S., Odabas, H., & Turan, N. (2026). Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis. Journal of Clinical Medicine, 15(5), 1853. https://doi.org/10.3390/jcm15051853

Vancouver

Oksuz S, Kinikoglu O, Ozkerim U, Isik D, Surmeli H, Ay S, et al. Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis. Journal of Clinical Medicine. 2026;15(5):1853. doi:10.3390/jcm15051853

BibTeX
@article{Oksuz2026,
  author = {Oksuz, Sila and Kinikoglu, Oguzcan and Ozkerim, Ugur and Isik, Deniz and Surmeli, Heves and Ay, Seval and Odabas, Hatice and Turan, Nedim},
  title = {Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  pages = {1853},
  doi = {10.3390/jcm15051853}
}
Kostenlos starten →